Exploring TROP2 Expression in Patients with NSCLC
Martin Dietrich, MD, PhD, and Wade Thomas Iams, MD, review the value of TROP2 as a target in patients with NSCLC.
EP: 1.Overview of Antibody Drug Conjugates in Lung Cancer
EP: 2.ADCs in Development for the Treatment of Lung Cancer
EP: 3.Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer
EP: 4.HER2-Directed Agents in NSCLC
EP: 5.Targeting HER3 in EGFR-Mutant NSCLC
Now Viewing
EP: 6.Exploring TROP2 Expression in Patients with NSCLC
Related Videos
Related Content
